title: Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre.
abstract: BACKGROUND
  Psoriasis is one of the most common inflammatory skin disorders. There are only limited data on systemic treatment in children.
  
  
  OBJECTIVE
  To assess the safety and clinical efficacy of the treatment of six paediatric patients with fumaric acid esters (FAE, Fumaderm) for psoriasis.
  
  
  METHODS
  Six patients aged 6-17 years were treated with FAE. Patients underwent regular assessment. Treatment efficacy was evaluated using the Psoriasis Area and Severity Index (PASI) and body surface area (BSA).
  
  
  RESULTS
  The mean duration of treatment was 17.8 months. PASI and BSA were determined after 12 weeks. All patients showed improvement in their skin condition, two achieving PASI75, one PASI90 and three PASI100 response. Proteinuria was encountered in one patient and two patients suffered from gastrointestinal discomfort. Treatment was discontinued due to remission in two patients.
  
  
  CONCLUSIONS
  Treatment with FAE in paediatric patients is a valuable alternative option when systemic treatment is needed.
authors.affiliation: Psoriasis Centre at the Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Steinz
authors.forename: Sascha
authors.initials: S
authors.lastname: Gerdes
authors.forename: Silja
authors.initials: S
authors.lastname: Domm
authors.forename: Ulrich
authors.initials: U
authors.lastname: Mrowietz
mesh_terms: D000046:Academic Medical Centers; D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069462:Dimethyl Fumarate; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005650:Fumarates / Q000008:administration & dosage* / Q000009:adverse effects; D005858:Germany; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy*; D012189:Retrospective Studies; D012494:Sampling Studies; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D005650:Fumarates; D000069462:Dimethyl Fumarate